▶ 調査レポート

遺伝子検査のグローバル市場(~2027):キャリア検査、診断検査、新生児スクリーニング、ファーマコゲノミクス、出生前検査

• 英文タイトル:Genetic Testing Market Research Report by Type, Technology, Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

360iResearchが調査・発行した産業分析レポートです。遺伝子検査のグローバル市場(~2027):キャリア検査、診断検査、新生児スクリーニング、ファーマコゲノミクス、出生前検査 / Genetic Testing Market Research Report by Type, Technology, Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 / MRC2304F072資料のイメージです。• レポートコード:MRC2304F072
• 出版社/出版日:360iResearch / 2022年10月
• レポート形態:英語、PDF、235ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥742,350 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,492,350 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iResearch社の本調査レポートによると、2021年に9,194.33百万ドルであった世界の遺伝子検査市場規模は2022年に10,456.80百万ドルになり、更に年平均13.90%拡大して2027年までに20,083.74百万ドルに達する見通しです。本書は、遺伝子検査の世界市場についての多面的な調査を元に、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別(キャリア検査、診断検査、新生児スクリーニング、ファーマコゲノミクス、出生前検査)分析、技術別(細胞遺伝学、DNAシーケンシング、遺伝子発現プロファイリング、マイクロアレイ、PCR)分析、用途別(自己免疫疾患、癌、慢性疾患、遺伝性疾患、神経変性疾患)分析、地域別(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)分析、競争状況、企業情報などの内容をまとめた市場調査レポートです。なお、本書に掲載されている企業情報には、Agilent Technologies, Inc.、Becton, Dickinson and Company、Bio-Rad Laboratories, Inc.、Centogene N.V.、Color Genomics, Inc.、Coopersurgical, Inc.、Eurofins Scientific SE、F. Hoffmann-La Roche AG、Fulgent Genetics, Incなどが含まれています。
・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界の遺伝子検査市場規模:種類別
- キャリア検査の市場規模
- 診断検査の市場規模
- 新生児スクリーニングの市場規模
- ファーマコゲノミクスの市場規模
- 出生前検査の市場規模
・世界の遺伝子検査市場規模:技術別
- 細胞遺伝学の市場規模
- DNAシーケンシングの市場規模
- 遺伝子発現プロファイリングの市場規模
- マイクロアレイの市場規模
- PCRの市場規模
・世界の遺伝子検査市場規模:用途別
- 自己免疫疾患における市場規模
- 癌における市場規模
- 慢性疾患における市場規模
- 遺伝性疾患における市場規模
- 神経変性疾患における市場規模
・世界の遺伝子検査市場規模:地域別
- 南北アメリカの遺伝子検査市場規模
アメリカの遺伝子検査市場規模
カナダの遺伝子検査市場規模
ブラジルの遺伝子検査市場規模
...
- アジア太平洋の遺伝子検査市場規模
日本の遺伝子検査市場規模
中国の遺伝子検査市場規模
インドの遺伝子検査市場規模
韓国の遺伝子検査市場規模
台湾の遺伝子検査市場規模
...
- ヨーロッパ/中東/アフリカの遺伝子検査市場規模
イギリスの遺伝子検査市場規模
ドイツの遺伝子検査市場規模
フランスの遺伝子検査市場規模
ロシアの遺伝子検査市場規模
...
- その他地域の遺伝子検査市場規模
・競争状況
・企業情報

The Global Genetic Testing Market size was estimated at USD 9,194.33 million in 2021 and expected to reach USD 10,456.80 million in 2022, and is projected to grow at a CAGR 13.90% to reach USD 20,083.74 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Genetic Testing to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the market was studied across Carrier Testing, Diagnostic Testing, New Born Screening, Pharmacogenomics, Preimplantation Testing, Prenatal Testing, and Presymptomatic and Predictive Testing.

Based on Technology, the market was studied across Cytogenetics, DNA Sequencing, Gene Expression Profiling, Microarrays, and PCR.

Based on Application, the market was studied across Autoimmune Disorders, Cancer, Chronic Diseases, Genetic Disorders, and Neurodegenerative Diseases.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Genetic Testing market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Genetic Testing Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Genetic Testing Market, including Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Centogene N.V., Color Genomics, Inc., Coopersurgical, Inc., Eurofins Scientific SE, F. Hoffmann-La Roche AG, Fulgent Genetics, Inc, Health Network Laboratories, L.P., Invitae Corporation, Laboratory Corporation of America Holdings, Macrogen, Inc., Myriad Genetics, Inc., OPKO Health, Inc., PerkinElmer Inc., PreventionGenetics LLC, Progenity, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Sanofi S.A., Strand Life Sciences Pvt. Ltd., and Thermo Fisher Scientific Inc..

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Genetic Testing Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Genetic Testing Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Genetic Testing Market?
4. What is the competitive strategic window for opportunities in the Global Genetic Testing Market?
5. What are the technology trends and regulatory frameworks in the Global Genetic Testing Market?
6. What is the market share of the leading vendors in the Global Genetic Testing Market?
7. What modes and strategic moves are considered suitable for entering the Global Genetic Testing Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing application of genetic testing in oncology and genetic diseases
5.1.1.2. Growing adoption of precision medicine diagnostic techniques
5.1.1.3. Rising implementation of personalized medicine applications to treat chronic disorders
5.1.1.4. Growing demand for direct-to-consumer genetic testing
5.1.2. Restraints
5.1.2.1. Lack of experienced professionals
5.1.2.2. Social and ethical implications of genetic testing
5.1.3. Opportunities
5.1.3.1. Stringent regulatory for product approvals
5.1.3.2. Technological advances in the field of genetic testing and panels for ECS
5.1.4. Challenges
5.1.4.1. High cost of next generation sequencing
5.2. Cumulative Impact of COVID-19

6. Genetic Testing Market, by Type
6.1. Introduction
6.2. Carrier Testing
6.3. Diagnostic Testing
6.4. New Born Screening
6.5. Pharmacogenomics
6.6. Preimplantation Testing
6.7. Prenatal Testing
6.8. Presymptomatic and Predictive Testing

7. Genetic Testing Market, by Technology
7.1. Introduction
7.2. Cytogenetics
7.3. DNA Sequencing
7.4. Gene Expression Profiling
7.5. Microarrays
7.6. PCR

8. Genetic Testing Market, by Application
8.1. Introduction
8.2. Autoimmune Disorders
8.3. Cancer
8.4. Chronic Diseases
8.5. Genetic Disorders
8.6. Neurodegenerative Diseases

9. Americas Genetic Testing Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Genetic Testing Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Genetic Testing Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Agilent Technologies, Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Becton, Dickinson and Company
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Bio-Rad Laboratories, Inc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Centogene N.V.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Color Genomics, Inc.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Coopersurgical, Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Eurofins Scientific SE
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. F. Hoffmann-La Roche AG
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Fulgent Genetics, Inc
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Health Network Laboratories, L.P.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Invitae Corporation
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Laboratory Corporation of America Holdings
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Macrogen, Inc.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Myriad Genetics, Inc.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. OPKO Health, Inc.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. PerkinElmer Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. PreventionGenetics LLC
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Progenity, Inc.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. QIAGEN N.V.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Quest Diagnostics Incorporated
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Sanofi S.A.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Strand Life Sciences Pvt. Ltd.
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Thermo Fisher Scientific Inc.
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing